• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用于生产针对16型和18型人乳头瘤病毒疫苗的L1蛋白的表位设计

Epitope design of L1 protein for vaccine production against Human Papilloma Virus types 16 and 18.

作者信息

Baidya Sunanda, Das Rasel, Kabir Md Golam, Arifuzzaman Md

机构信息

Department of Biochemistry & Molecular Biology, University of Chittagong, Chittagong 4331, Bangladesh.

Leibniz Institute for Surface Modification, Permoserstraße 15, 04318 Leipzig, Germany.

出版信息

Bioinformation. 2017 Mar 31;13(3):86-93. doi: 10.6026/97320630013086. eCollection 2017.

DOI:10.6026/97320630013086
PMID:28584449
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5450250/
Abstract

Cervical cancer accounts for about two-thirds of all cancer cases linked etiologically to Human Papilloma Virus (HPV). 15 oncogenic HPV types can cause cervical cancer, of which HPV16 and HPV18 combinedly account for about 70% of it. So, effective epitope design for the clinically relevant HPV types 16 and 18 would be of major medical benefit. Here, a comprehensive analysis is carried out to predict the epitopes against HPV types 16 and 18 through "reverse vaccinology" approach. We attempted to identify the evolutionarily conserved regions of major capsid protein (L1) as well as minor capsid protein (L2) of HPV and designed epitopes within these regions. In this study, we analyzed about 49 and 27 sequences of HPV L2 and L1 proteins respectively. Since we found that the intertype variability of L2 is higher than for L1 proteins, our analysis was emphasized on epitopes of L1 of HPV types 16 and 18. We had selected HLA-A0201, DRB11501, DQB10602, DRB10401 and DQB1*0301 alleles for the prediction of T cell epitopes of L1 of HPV 16 and 18. Finally, we reported that predicted epitope sequences EEYDLQFIFQLCKITLTA, and RHGEEYDLQFIFQLCKITLTA of L1 protein of HPV 16, and LPDPNKF, PETQRLVWAC, PVPGQYDA, YNPETQRLVWAC, DTGYGAMD, PVPGQYDATK, KQDIPKVSAYQYRVFRV, RDNVSVDYKQTQLCI and YSRHVEEYDLQFIF of L1 protein of HPV 18 could be therapeutic tools for vaccine design against HPV.

摘要

宫颈癌约占所有病因与人类乳头瘤病毒(HPV)相关的癌症病例的三分之二。15种致癌性HPV类型可导致宫颈癌,其中HPV16和HPV18共同约占70%。因此,针对临床相关的HPV16和HPV18型进行有效的表位设计将具有重大医学益处。在此,通过“反向疫苗学”方法对针对HPV16和18型的表位进行了全面分析。我们试图确定HPV主要衣壳蛋白(L1)以及次要衣壳蛋白(L2)的进化保守区域,并在这些区域内设计表位。在本研究中,我们分别分析了约49条和27条HPV L2和L1蛋白序列。由于我们发现L2的型间变异性高于L1蛋白,我们的分析重点放在了HPV16和18型L1的表位上。我们选择了HLA - A0201、DRB11501、DQB10602、DRB10401和DQB1*0301等位基因来预测HPV16和18型L1的T细胞表位。最后,我们报告称,HPV16型L1蛋白的预测表位序列EEYDLQFIFQLCKITLTA和RHGEEYDLQFIFQLCKITLTA,以及HPV18型L1蛋白的LPDPNKF、PETQRLVWAC、PVPGQYDA、YNPETQRLVWAC、DTGYGAMD、PVPGQYDATK、KQDIPKVSAYQYRVFRV、RDNVSVDYKQTQLCI和YSRHVEEYDLQFIF可作为针对HPV疫苗设计的治疗工具。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5819/5450250/3238b583a4a6/97320630013086F6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5819/5450250/13968b5ecf5a/97320630013086F1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5819/5450250/913c7ba835bd/97320630013086F2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5819/5450250/3ab618e8b55f/97320630013086F3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5819/5450250/6cedebdce645/97320630013086F4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5819/5450250/02de9df90c89/97320630013086F5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5819/5450250/3238b583a4a6/97320630013086F6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5819/5450250/13968b5ecf5a/97320630013086F1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5819/5450250/913c7ba835bd/97320630013086F2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5819/5450250/3ab618e8b55f/97320630013086F3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5819/5450250/6cedebdce645/97320630013086F4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5819/5450250/02de9df90c89/97320630013086F5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5819/5450250/3238b583a4a6/97320630013086F6.jpg

相似文献

1
Epitope design of L1 protein for vaccine production against Human Papilloma Virus types 16 and 18.用于生产针对16型和18型人乳头瘤病毒疫苗的L1蛋白的表位设计
Bioinformation. 2017 Mar 31;13(3):86-93. doi: 10.6026/97320630013086. eCollection 2017.
2
Minor Capsid Protein L2 Polytope Induces Broad Protection against Oncogenic and Mucosal Human Papillomaviruses.次要衣壳蛋白L2多表位诱导针对致癌性和黏膜型人乳头瘤病毒的广泛保护。
J Virol. 2018 Jan 30;92(4). doi: 10.1128/JVI.01930-17. Print 2018 Feb 15.
3
Motif analysis of HLA class II molecules that determine the HPV associated risk of cervical carcinogenesis.决定人乳头瘤病毒(HPV)相关宫颈癌发生风险的人类白细胞抗原(HLA)II类分子的基序分析
Int J Mol Med. 2001 Oct;8(4):405-12. doi: 10.3892/ijmm.8.4.405.
4
In silico/In vivo analysis of high-risk papillomavirus L1 and L2 conserved sequences for development of cross-subtype prophylactic vaccine.高危型人乳头瘤病毒 L1 和 L2 保守序列的计算机模拟/体内分析,用于开发跨亚型预防性疫苗。
Sci Rep. 2019 Oct 23;9(1):15225. doi: 10.1038/s41598-019-51679-8.
5
Dissection of Capsid Protein HPV 52 to Rationalize Vaccine Designs Using Computational Approaches Immunoinformatics and Molecular Docking.HPV 52 衣壳蛋白的剖析以使用计算方法免疫信息学和分子对接来合理化疫苗设计。
Asian Pac J Cancer Prev. 2022 Jul 1;23(7):2243-2253. doi: 10.31557/APJCP.2022.23.7.2243.
6
Chimeric human papillomavirus type 16 (HPV-16) L1 particles presenting the common neutralizing epitope for the L2 minor capsid protein of HPV-6 and HPV-16.呈现人乳头瘤病毒6型(HPV-6)和人乳头瘤病毒16型(HPV-16)次要衣壳蛋白L2共同中和表位的嵌合人乳头瘤病毒16型(HPV-16)L1颗粒。
J Virol. 2003 Aug;77(15):8386-93. doi: 10.1128/jvi.77.15.8386-8393.2003.
7
Worldwide genetic variations in high-risk human papillomaviruses capsid L1 gene and their impact on vaccine efficiency.高危型人乳头瘤病毒衣壳 L1 基因的全球遗传变异及其对疫苗效率的影响。
Gene. 2021 May 25;782:145533. doi: 10.1016/j.gene.2021.145533. Epub 2021 Feb 23.
8
Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles.由L1/L2嵌合病毒样颗粒组成的人乳头瘤病毒疫苗在临床前模型中诱导产生广泛的交叉保护作用。
J Virol. 2016 Jun 24;90(14):6314-25. doi: 10.1128/JVI.00449-16. Print 2016 Jul 15.
9
Combination of human papillomaviruses L1 and L2 multiepitope constructs protects mice against tumor cells.人乳头瘤病毒L1和L2多表位构建体的组合可保护小鼠免受肿瘤细胞侵害。
Fundam Clin Pharmacol. 2021 Dec;35(6):1055-1068. doi: 10.1111/fcp.12690. Epub 2021 Jun 16.
10
Capsid display of a conserved human papillomavirus L2 peptide in the adenovirus 5 hexon protein: a candidate prophylactic hpv vaccine approach.人乳头瘤病毒L2保守肽在腺病毒5型六邻体蛋白中的衣壳展示:一种候选预防性人乳头瘤病毒疫苗方法。
Virol J. 2015 Sep 11;12:140. doi: 10.1186/s12985-015-0364-7.

引用本文的文献

1
Molecular Analysis and Bioinformatics Assessment of Full-Length L1 Gene of Bovine Papillomavirus Type-1 as a Potential DNA Vaccine Study.牛乳头瘤病毒1型全长L1基因作为潜在DNA疫苗研究的分子分析与生物信息学评估
Vet Med Int. 2025 Apr 10;2025:6785087. doi: 10.1155/vmi/6785087. eCollection 2025.
2
Designing and immunomolecular analysis of a new broad-spectrum multiepitope vaccine against divergent human papillomavirus types.针对多种不同人类乳头瘤病毒类型的新型广谱多表位疫苗的设计及免疫分子分析
PLoS One. 2024 Dec 2;19(12):e0311351. doi: 10.1371/journal.pone.0311351. eCollection 2024.
3
Designing multi-epitope based peptide vaccine candidates against SARS-CoV-2 using immunoinformatics approach.

本文引用的文献

1
Epitomics: IgG-epitome decoding of E6, E7 and L1 proteins from oncogenic human papillomavirus type 58.表位组学:从致癌性人乳头瘤病毒 58 型中 E6、E7 和 L1 蛋白的 IgG-表位解码
Sci Rep. 2016 Oct 6;6:34686. doi: 10.1038/srep34686.
2
Rational Design of Peptide Vaccines Against Multiple Types of Human Papillomavirus.针对多种类型人乳头瘤病毒的肽疫苗的合理设计
Cancer Inform. 2016 Jun 1;15(Suppl 1):1-16. doi: 10.4137/CIN.S39071. eCollection 2016.
3
Targeting of HPV-16+ Epithelial Cancer Cells by TCR Gene Engineered T Cells Directed against E6.
运用免疫信息学方法设计针对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的多表位肽疫苗候选物。
Bioimpacts. 2022;12(4):359-370. doi: 10.34172/bi.2022.23769. Epub 2022 Feb 27.
4
RG1-VLP and Other L2-Based, Broad-Spectrum HPV Vaccine Candidates.RG1病毒样颗粒及其他基于L2的广谱人乳头瘤病毒候选疫苗
J Clin Med. 2021 Mar 3;10(5):1044. doi: 10.3390/jcm10051044.
5
Advances in Designing and Developing Vaccines, Drugs and Therapeutic Approaches to Counter Human Papilloma Virus.设计和开发疫苗、药物和治疗方法以对抗人类乳头瘤病毒的进展。
Front Immunol. 2018 Nov 12;9:2478. doi: 10.3389/fimmu.2018.02478. eCollection 2018.
针对E6的TCR基因工程T细胞对HPV-16阳性上皮癌细胞的靶向作用。
Clin Cancer Res. 2015 Oct 1;21(19):4431-9. doi: 10.1158/1078-0432.CCR-14-3341.
4
Design, Immune Responses and Anti-Tumor Potential of an HPV16 E6E7 Multi-Epitope Vaccine.一种HPV16 E6E7多表位疫苗的设计、免疫反应及抗肿瘤潜力
PLoS One. 2015 Sep 21;10(9):e0138686. doi: 10.1371/journal.pone.0138686. eCollection 2015.
5
Global cancer statistics, 2012.全球癌症统计数据,2012 年。
CA Cancer J Clin. 2015 Mar;65(2):87-108. doi: 10.3322/caac.21262. Epub 2015 Feb 4.
6
Prediction of promiscuous epitopes in the e6 protein of three high risk human papilloma viruses: a computational approach.三种高危型人乳头瘤病毒E6蛋白中混杂表位的预测:一种计算方法
Asian Pac J Cancer Prev. 2013;14(7):4167-75. doi: 10.7314/apjcp.2013.14.7.4167.
7
Conformational B-cell epitope prediction on antigen protein structures: a review of current algorithms and comparison with common binding site prediction methods.抗原蛋白结构上的构象 B 细胞表位预测:当前算法综述及与常见结合位点预测方法比较。
PLoS One. 2013 Apr 19;8(4):e62249. doi: 10.1371/journal.pone.0062249. Print 2013.
8
PREDIVAC: CD4+ T-cell epitope prediction for vaccine design that covers 95% of HLA class II DR protein diversity.PREDIVAC:用于疫苗设计的 CD4+ T 细胞表位预测,涵盖 95%的 HLA Ⅱ类 DR 蛋白多样性。
BMC Bioinformatics. 2013 Feb 14;14:52. doi: 10.1186/1471-2105-14-52.
9
Management strategies and cost effectiveness in the prevention of cervical cancer.宫颈癌预防中的管理策略与成本效益
Clinicoecon Outcomes Res. 2009;1:17-23. doi: 10.2147/ceor.s4226. Epub 2009 Jun 5.
10
Epitope-driven DNA vaccine design employing immunoinformatics against B-cell lymphoma: a biotech's challenge.基于免疫信息学的针对 B 细胞淋巴瘤的表位驱动型 DNA 疫苗设计:生物技术的挑战。
Biotechnol Adv. 2012 Jan-Feb;30(1):372-83. doi: 10.1016/j.biotechadv.2011.06.020. Epub 2011 Jul 2.